- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: June 17, 2025
Author(s):
Key Takeaways
- Oral Ritlecitinib with nbUV-B accelerates repigmentation in nonsegmental vitiligo, improving patient outcomes and quality of life.
- The INTEGUMENT-INFANT trial investigates Roflumilast 0.05% cream as a non-steroidal treatment for infant atopic dermatitis.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Oral Ritlecitinib Plus nbUV-B Accelerates Repigmentation in Nonsegmental Vitiligo
Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.
Investigating Roflumilast 0.05% Cream for Infant AD with Mercedes E. Gonzalez, MD
Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.
Christina Feser, DO, Shares Therapeutic Advances in Hidradenitis Suppurativa From SCALE 2025
At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.
Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 2
Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.
Recap: 2025 Revolutionizing Atopic Dermatitis Conference
Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
